When IBD patients self-report their adverse reactions to biological therapies, they could provide insights that shape and optimize treatments.
That’s the goal of a recently created pharmacovigilance system to survey how patients think about and reacted to drug therapies. Understanding the patient experience could ultimately help bolster treatments, according to Pepjin Thomas, a doctoral candidate in the Department of Gastroenterology at Radboud University Medical Center, in Nijmegen, the